<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Initial treatment of metastatic triple-negative breast cancer</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Initial treatment of metastatic triple-negative breast cancer</h1>
<div class="graphic"><div class="figure"><div class="ttl">Initial treatment of metastatic triple-negative breast cancer</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_lgnd">This algorithm illustrates our general approach to the management of patients with "triple-negative breast cancer" as defined as those that lack expression of ER, PR, and HER2. We consider "triple-negative" to mean cancers that have ≤1% expression of ER and PR as determined by IHC, and that are either 0 to 1+ by IHC, or IHC 2+ and FISH negative (not amplified). When possible, these studies should be performed on a metastatic lesion since discordance between primary and metastatic lesions is seen in a sizeable minority of patients.</div><div class="graphic_footnotes"><em>BRCA</em>: breast cancer susceptibility gene; PD-L1: programmed cell death-ligand 1; PARP: polyadenosine diphosphate-ribose polymerase; ER: estrogen receptor; PR: progesterone receptor; HER2: human epidermal growth factor receptor 2; IHC: immunohistochemistry; FISH: fluorescence in situ hybridization; FDA: US Food and Drug Administration; OS: overall survival; TNBC: triple-negative breast cancer; CPS: combined positive score.<br/>* Combination chemotherapy may be appropriate for those with extensive or rapidly progressive visceral disease, in whom the higher chance of response is thought to outweigh the higher risks of toxicity due to concerns about impending organ dysfunction. However, it should be recognized that no prospective data have shown combination chemotherapy improves overall survival compared with single-agent sequential cytotoxic chemotherapy.<br/>¶ We often start with a PARP inhibitor rather than chemotherapy given the potential for disease control with fewer toxicities compared with chemotherapy, and proceed with atezolizumab and nabpaclitaxel upon progression. However, some experts reasonably offer atezolizumab and nabpaclitaxel ahead of a PARP inhibitor for those with PD-L1-positive, <em>BRCA</em>-positive, triple-negative breast cancer.<br/>Δ Pembrolizumab is approved by the FDA in combination with chemotherapy for patients with metastatic TNBC whose tumors express PD-L1 with a CPS ≥10 (the percentage of total cells [tumor cells, lymphocytes, macrophages] that stain for PD-L1).<sup>[1] </sup>Although atezolizumab previously was granted accelerated approval, regulatory approval has been withdrawn given subsequent trial results.<br/><span class="lozenge">◊</span> For <em>BRCA</em>-associated breast cancers, taxanes and platinum agents appear to be equally effective as first-line agents. By contrast, for non-<em>BRCA</em>-associated breast cancers, platinum-based chemotherapy has inferior response rates when compared with taxane-based treatment in the first-line setting.</div><div class="graphic_reference">Reference:

<ol>
<li>Pembrolizumab injection. United States Prescribing Information. US National Library of Medicine. (Available online at <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s088lbl.pdf" target="_blank">accessdata.fda.gov/drugsatfda_docs/label/2020/125514s088lbl.pdf</a>, accessed on November 13, 2020).</li>
</ol></div><div id="graphicVersion">Graphic 121095 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
